Cardiac Metastases of Neuroendocrine Tumors Treated With 177Lu DOTATATE Peptide Receptor Radionuclide Therapy or 131I-MIBG Therapy. (December 2015)

• Record Type: Journal Article
• Authors: Makis, William; McCann, Karey; Bryanton, Mark; McEwan, Alexander J.B.
• Is Part Of: Clinical nuclear medicine. Volume 40:Number 12(2015)
• Publication Date: 2015-12
• Subjects: peptide receptor radionuclide therapy -- 177Lu DOTATATE -- 131I-MIBG -- neuroendocrine tumor -- NET -- cardiac metastasis; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000000963
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Neuroendocrine tumors have a propensity to metastasize to the heart, although the reason for this remains unknown. A review of 251 neuroendocrine tumor patients treated with 177 Lu DOTATATE peptide receptor radionuclide therapy or 131 I-MIBG therapy at our institution since 2003 revealed 2 patients with cardiac metastases (incidence, 0.8%), one treated with 177 Lu DOTATATE and one with 131 I-MIBG. We present the imaging findings of these 2 patients, as well as their management and responses to therapy.